Skip to main content
Pentixapharm Holding AG logo

Pentixapharm Holding AG — Investor Relations & Filings

Ticker · PTP ISIN · DE000A40AEG0 LEI · 3912005VBOVXNDXEQZ36 F Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2025-03-18 Report Publication Anno…
Country DE Germany
Listing F PTP

About Pentixapharm Holding AG

https://www.pentixapharm.com/

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG". It explicitly states that the Annual financial report of the group will be disclosed on a future date (April 15, 2025) and provides a link to where it will be available. According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement stating that a report will be published or is attached classifies the document as a Report Publication Announcement (RPA), not the report itself (which would be 10-K in this case). The document's short length (2006 chars) and its function as a notice of future publication strongly support the RPA classification.
2025-03-18 English
Hinweis auf Konzernabschluss vom 02.10.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 100% confidence The document is a short notification (766 characters) announcing the availability of a financial report ('Hinweis auf Konzernabschluss'). It provides a link to the website where the report can be found and specifies the publication date. Per the 'Menu vs Meal' rule, since this is a short announcement regarding the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-03-18 German
Hinweis auf Konzernabschluss vom 02.10.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) that explicitly states the financial report is available at a specific URL. It does not contain the actual financial statements or analysis, but rather serves as a formal announcement of the report's publication. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-03-18 German
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
Board/Management Information Classification · 100% confidence The document explicitly announces 'Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG'. It details the return of Dr. Andreas Eckert to the Supervisory Board and changes in the composition of the Management Board, including the departure of Frank Perschmann. This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-03-04 English
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
Board/Management Information Classification · 100% confidence The document explicitly announces 'Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG'. It details the return of Dr. Andreas Eckert to the Supervisory Board and changes in the composition of the Management Board, including the departure of Frank Perschmann. This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-03-03 English
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharms Lu177-PentixaTher to be Presented at ASCO-GU 2025
Regulatory Filings Classification · 100% confidence The document is a short news release dated February 13, 2025, announcing that clinical data regarding a treatment (Lu177-PentixaTher) will be presented at an upcoming medical conference (ASCO-GU 2025). It contains key highlights, presentation details, and company boilerplate information. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing a specific event like a dividend or director dealing. Since it is an announcement about company news/developments distributed via a news service (EQS News), and it doesn't fit the specific categories like ER, CAP, or DIV, it falls best under the general Regulatory Filings/News category, which is RNS, as it is a general corporate news dissemination.
2025-02-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.